Research programme: therapeutic antibodies - Bayer HealthCare/Shire
Latest Information Update: 29 Jan 2016
At a glance
- Originator Bayer Schering Pharma; Dyax
- Developer Bayer HealthCare Pharmaceuticals; Shire
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified